Alan Skarbnik (@ASkarbnik), MD, director of the lymphoma and CLL program, Novant Health (Charlotte, NC), and Aaron Goodman (@AaronGoodman33), MD, hematologist, University of California San Diego, join the show for a long-awaited debate: treating double-hit lymphoma with R-CHOP vs dose-adjusted (DA)-EPOCH-R. The conversation gets testy when the trio describe ... Show More
Oct 7
The Truth About 340B With Anthony DiGiorgio
Returning guest Anthony DiGiorgio, DO, a practicing neurosurgeon at UCSF and noted health policy commentator, takes a deep dive into the 340B Drug Pricing Program—one of the most consequential yet misunderstood mechanisms in US healthcare. He traces the program’s origins in the e ... Show More
35m 54s
Sep 30
Longevity Clinic and Concierge Medicine With Anand Patel
Dr. Anand Patel, DO, founder of LV8 Health, walks us through the philosophy and mechanics of concierge-style longevity medicine. He explains how LV8 applies Medicine 3.0, combining precision diagnostics (DEXA, VO₂ max, resting metabolic rate, advanced blood panels) with regenerat ... Show More
47m 19s
Apr 2023
Episode 234: Amar Kishan, MD, on Neoadjuvant or Adjuvant Radiotherapy for Prostate Cancer
In the first part of our Hollywood tour, Amar Kishan, MD,
joins us to discuss his recent meta-analysis published in the Journal of
Clinical Oncology on the effects of concurrent adjuvant sequencing versus
neoadjuvant concurrent sequencing. Dr. Kishan also gives an overview of the ... Show More
20m 35s
Dec 2021
Knowledge and Practice Patterns Among Pulmonologists for Molecular Biomarker Testing in Advanced NSCLC
CHEST December 2021, Volume 160, Issue 6 Gerard A. Silvestri, MD, FCCP, and Adam H. Fox, MD, join CHEST Podcast Moderator Dominique Pepper, MD, to discuss the current knowledge and practice of pulmonologists regarding biomarker testing and targeted therapies in advanced non-small ... Show More
32m 8s
Jan 2024
What’s New in Prostate Cancer, RCC, and mUC at GU24
Drs. Neeraj Agarwal and Jeanny Aragon-Ching discuss several key abstracts to be presented at the 2024 ASCO GU Cancers Symposium, including sequencing versus upfront combination therapies for mCRPC in the BRCAAway study, updates on the CheckMate-9ER and CheckMate-214 trials in ccR ... Show More
25m 10s